World-first clinical trial for sarcoma
2021-03-26
Recruitment is now open for a national clinical trial
The trial will test whether an existing therapy for psoriasis can help treat patients with sarcomas, which are rare cancers arising in the connective tissues (bone, muscle, tendons, nerves, fat, cartilage and blood vessels) and may occur anywhere in the body. In particular, the trial focuses on osteosarcoma, a rare but aggressive form of bone cancer that most commonly affects teenagers and young adults.
The phase II clinical trial, which is a collaboration between the Garvan Institute of Medical Research, Omico (the Australian Genomic Cancer Medicine Centre) and the University of Sydney’s NHMRC Clinical Trials Centre, will investigate if treatment with a drug targeting the immune molecule IL23 could improve outcomes for sarcoma patients.
Read more: Targeting IL-23 in bone and soft tissue sarcomas
The new trial is the first globally to test a new anticancer pathway for sarcoma. It is supported by the Cooper Rice-Brading Foundation, the Australian Government, the NSW Office of Health and Medical Research, SunPharma, The Kids’ Cancer Project, the Matthew Fisher Sarcoma Research Fund and the Daniel Allchin Race for a Cure, and brings new hope to those affected by sarcoma.
Study chief investigator Professor David Thomas, Head of the Genomic Cancer Medicine Laboratory at Garvan, Director of The Kinghorn Cancer Centre and CEO of Omico (pictured top centre of header image) explains:
This immunotherapy trial is part of our national Molecular Screening and Therapeutics (MoST) trials program, and will be open in at least eight centres nationally...
Sarcomas are aggressive cancers with few treatment options. For osteosarcoma in particular, there have been few advances in treatments for this form of cancer in four decades. We hope that this clinical trial, which will investigate if treating patients with a sarcoma with a medication currently in use for another condition will have anti-cancer effects.
Immunotherapy for osteosarcoma
Sarcomas are rare cancers of connective tissues such as fat, muscle and bone. They particularly affect the young, with osteosarcoma, or bone sarcoma, among the ten most common cancers affecting Australians between ages 15 to 29.
The five-year survival rate for sarcomas remains as low as 65 per cent, while options for patients with incurable disease are very limited.
The new clinical trial follows an earlier study that demonstrated the immune molecule IL23 is central to the development and progression of soft-tissue and bone sarcoma in animal models. By targeting IL23, the study authors were able to successfully shrink osteosarcoma tumours in mice.
Dr Maya Kansara who leads the Immunobiology of Cancer Group at the Garvan Institute explains:
Our previous research showed us that when we blocked IL23 in mice with osteosarcoma, their tumour growth slowed...We hope that our promising pre-clinical results will translate to improved clinical outcomes in osteosarcoma patients.
The trial, opened to enrolment this month, will examine how patients with advanced osteosarcoma and soft tissue sarcomas respond to the anti-IL23-targeting treatment. It is a single-arm, open-label phase II trial design which means all 32 sarcoma patients planned to be recruited will receive the treatment. Professor Thomas continues:
If we see promising signs from this initial study, we believe that targeting IL23 may play a role in the treatment of many cancer types.
Robert Beech-Jones, Chairman of the Cooper Rice-Brading Foundation, expressed:
CRBF is delighted to have the opportunity to support this highly significant research. We thank Professor David Thomas and Dr Maya Kansara and the highly accomplished team behind this research, for the hope this world first study provides to sarcoma patients. This exemplifies the high level research Cooper envisaged this Foundation would support.